Recent technical strategies to identify diagnostic biomarkers for ovarian cancer

References

• Hartwell L, Mankoff D, Paulovich A, Ramsey S, Swisher E. Cancer biomarkers: a systems approach. Nat. Biotechnol.24(8), 905–908 (2006).
   PubMed Web of Science ®Google Scholar
• Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol. Cell. Proteomics3(4), 355–366 (2004).
   PubMed Web of Science ®Google Scholar
• Skates SJ, Xu FJ, Yu YH et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer76(10 Suppl.), 2004–2010 (1995).
   PubMed Web of Science ®Google Scholar
• Zurawski VR Jr, Sjovall K, Schoenfeld DA et al. Prospective evaluation of serum CA 125 levels in a normal population, Phase I: the specificities of single and serial determinations in testing for ovarian cancer. Gynecol. Oncol.36(3), 299–305 (1990).
   PubMed Web of Science ®Google Scholar
• Jacobs IJ, Oram DH, Bast RC Jr. Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15–3, and TAG 72.3. Obstet. Gynecol.80(3 Pt 1), 396–399 (1992).
   PubMed Web of Science ®Google Scholar
• Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol.24(8), 971–983 (2006).
   PubMed Web of Science ®Google Scholar
• Mor G, Visintin I, Lai Y et al. Serum protein markers for early detection of ovarian cancer. Proc. Natl Acad. Sci. USA102(21), 7677–7682 (2005).
   PubMed Web of Science ®Google Scholar
• Terry KL, Sluss PM, Skates SJ et al. Blood and urine markers for ovarian cancer: a comprehensive review. Dis. Markers20(2), 53–70 (2004).
   PubMedGoogle Scholar
• Adonakis GL, Paraskevaidis E, Tsiga S, Seferiadis K, Lolis DE. A combined approach for the early detection of ovarian cancer in asymptomatic women. Eur. J. Obstet. Gynecol. Reprod. Biol.65(2), 221–22 (1996).
   PubMed Web of Science ®Google Scholar
• Bast RC Jr, Klug TL, St John E et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med.309(15), 883–887 (1983).
   PubMed Web of Science ®Google Scholar
• Inoue M, Fujita M, Nakazawa A, Ogawa H, Tanizawa O. Sialyl-Tn, sialyl-Lewis Xi, CA 19-9, CA 125, carcinoembryonic antigen, and tissue polypeptide antigen in differentiating ovarian cancer from benign tumors. Obstet. Gynecol.79(3), 434–440 (1992).
   PubMedGoogle Scholar
• Kudoh K, Kikuchi Y, Kita T et al. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma. Gynecol. Obstet. Invest.47(1), 52–57 (1999).
   PubMedGoogle Scholar
• Molina R, Ojeda B, Filella X et al. A prospective study of tumor markers CA 125 and CA 19.9 in patients with epithelial ovarian carcinomas. Tumour Biol.13(5–6), 278–286 (1992).
   PubMedGoogle Scholar
• Tholander B, Taube A, Lindgren A et al. Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase, in patients with ovarian carcinoma, borderline tumors, or benign adnexal masses: relevance for differential diagnosis. Gynecol. Oncol.39(1), 16–25 (1990).
   PubMed Web of Science ®Google Scholar
• Tamakoshi K, Kikkawa F, Shibata K et al. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor. Gynecol. Oncol.62(1), 67–72 (1996).
   PubMed Web of Science ®Google Scholar
• van Haaften-Day C, Shen Y, Xu F et al. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer92(11), 2837–2844 (2001).
   PubMed Web of Science ®Google Scholar
• Woolas RP, Conaway MR, Xu F et al. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol. Oncol.59(1), 111–116 (1995).
   PubMed Web of Science ®Google Scholar
• Woolas RP, Xu FJ, Jacobs IJ et al. Elevation of multiple serum markers in patients with Stage I ovarian cancer. J. Natl Cancer Inst.85(21), 1748–1751 (1993).
   PubMedGoogle Scholar
• Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J. Biol. Chem.276(29), 27371–27375 (2001).
   PubMed Web of Science ®Google Scholar
• Bast RC Jr, Knauf S, Epenetos A et al. Coordinate elevation of serum markers in ovarian cancer but not in benign disease. Cancer68(8), 1758–1763 (1991).
   PubMed Web of Science ®Google Scholar
• Feng H, Ghazizadeh M, Konishi H, Araki T. Expression of MUC1 and MUC2 mucin gene products in human ovarian carcinomas. Jpn. J. Clin. Oncol.32(12), 525–529 (2002).
   PubMed Web of Science ®Google Scholar
• Scambia G, Benedetti Panici P, Baiocchi G et al. CA 15-3 as a tumor marker in gynecological malignancies. Gynecol. Oncol.30(2), 265–273 (1988).
   PubMed Web of Science ®Google Scholar
• Diamandis EP, Scorilas A, Fracchioli S et al. Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J. Clin. Oncol.21(6), 1035–1043 (2003).
   PubMed Web of Science ®Google Scholar
• Luo LY, Katsaros D, Scorilas A et al. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res.63(4), 807–811 (2003).
   PubMed Web of Science ®Google Scholar
• Xu FJ, Ramakrishnan S, Daly L et al. Increased serum levels of macrophage colony-stimulating factor in ovarian cancer. Am. J. Obstet. Gynecol.165(5 Pt 1), 1356–1362 (1991).
   PubMed Web of Science ®Google Scholar
• Kim JH, Herlyn D, Wong KK et al. Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. Clin. Cancer Res.9(13), 4782–4791 (2003).
   PubMed Web of Science ®Google Scholar
• Kim JH, Skates SJ, Uede T et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA287(13), 1671–1679 (2002).
   PubMed Web of Science ®Google Scholar
• Ye B, Cramer DW, Skates SJ et al. Haptoglobin-α subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin. Cancer Res.9(8), 2904–2911 (2003).
   PubMed Web of Science ®Google Scholar
• Hellstrom I, Raycraft J, Hayden-Ledbetter M et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res.63(13), 3695–3700 (2003).
   PubMed Web of Science ®Google Scholar
• Scholler N, Crawford M, Sato A et al. Bead-based ELISA for validation of ovarian cancer early detection markers. Clin. Cancer Res.12(7 Pt 1), 2117–2124 (2006).
   PubMed Web of Science ®Google Scholar
• Simon I, Zhuo S, Corral L et al. B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res.66(3), 1570–1575 (2006).
   PubMed Web of Science ®Google Scholar
• Mok SC, Chao J, Skates S et al. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J. Natl Cancer Inst.93(19), 1458–1464 (2001).
   PubMed Web of Science ®Google Scholar
• McIntosh MW, Drescher C, Karlan B et al. Combining CA125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol. Oncol.95(1), 9–15 (2004).
   PubMed Web of Science ®Google Scholar
• Sutphen R, Xu Y, Wilbanks GD et al. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol. Biomarkers Prev.13(7), 1185–1191 (2004).
   PubMed Web of Science ®Google Scholar
• Zhang Z, Bast RC Jr, Yu Y et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res.64(16), 5882–5890 (2004).
   PubMed Web of Science ®Google Scholar
• Moore LE, Fung ET, McGuire M et al. Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population. Cancer Epidemiol. Biomarkers Prev.15(9), 1641–1646 (2006).
   PubMed Web of Science ®Google Scholar
• Gorelik E, Landsittel DP, Marrangoni AM et al. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol. Biomarkers Prev.14(4), 981–987 (2005).
   PubMed Web of Science ®Google Scholar
• Skates S, Iliopoulos O. Molecular markers for early detection of renal carcinoma: investigative approach. Clin. Cancer Res.10(18 Pt 2), 6296S–6301S (2004).
   Google Scholar
• Vaught JB. Biorepository and biospecimen science: a new focus for CEBP. Cancer Epidemiol. Biomarkers Prev.15(9), 1572–1573 (2006).
   PubMedGoogle Scholar
• Ambrosone CB, Nesline MK, Davis W. Establishing a cancer center data bank and biorepository for multidisciplinary research. Cancer Epidemiol. Biomarkers Prev.15(9), 1575–1577 (2006).
   PubMedGoogle Scholar
• Tworoger SS, Hankinson SE. Collection, processing, and storage of biological samples in epidemiologic studies: sex hormones, carotenoids, inflammatory markers, and proteomics as examples. Cancer Epidemiol. Biomarkers Prev.15(9), 1578–1581 (2006).
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Nagano M, Torada N et al. Urine diacetylspermine as a novel tumor marker for pancreatobiliary carcinomas. Rinsho Byori52(4), 336–339 (2004).
   PubMedGoogle Scholar
• Takahashi K, Hiramatsu K, Kawakita M et al. The significance of urine di-acetyl spermine level as a cancer marker for colorectal cancer. Rinsho Byori52(4), 332–335 (2004).
   PubMedGoogle Scholar
• Travis RC, Allen DS, Fentiman IS, Key TJ. Melatonin and breast cancer: a prospective study. J. Natl Cancer Inst.96(6), 475–482 (2004).
   PubMed Web of Science ®Google Scholar
• Ikematsu S, Okamoto K, Yoshida Y et al. High levels of urinary midkine in various cancer patients. Biochem. Biophys. Res. Commun.306(2), 329–332 (2003).
   PubMedGoogle Scholar
• Ye B, Skates S, Mok SC et al. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin. Cancer Res.12(2), 432–441 (2006).
   PubMed Web of Science ®Google Scholar
• Skates S, Troiano R, Knapp RC. Longitudinal CA125 detection of sporadic papillary serous carcinoma of the peritoneum. Int. J. Gynecol. Cancer13(5), 693–696 (2003).
   PubMedGoogle Scholar
• McIntosh MW, Urban N, Karlan B. Generating longitudinal screening algorithms using novel biomarkers for disease. Cancer Epidemiol. Biomarkers Prev.11(2), 159–166 (2002).
   PubMedGoogle Scholar
• Petricoin EF, Ardekani AM, Hitt BA et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet.359(9306), 572–577 (2002).
   PubMed Web of Science ®Google Scholar
• Villanueva J, Philip J, Entenberg D et al. Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal. Chem.76(6), 1560–1570 (2004).
   PubMed Web of Science ®Google Scholar
• Diamandis EP, van der Merwe DE. Plasma protein profiling by mass spectrometry for cancer diagnosis: opportunities and limitations. Clin. Cancer Res.11(3), 963–965 (2005).
   PubMed Web of Science ®Google Scholar
• Maruvada P, Wang W, Wagner PD, Srivastava S. Biomarkers in molecular medicine: cancer detection and diagnosis. Biotechniques (Suppl.), 9–15 (2005).
   Google Scholar
• Zolg JW, Langen H. How industry is approaching the search for new diagnostic markers and biomarkers. Mol. Cell. Proteomics3(4), 345–354 (2004).
   PubMed Web of Science ®Google Scholar
• Qin S, Ferdinand AS, Richie JP et al. Chromatofocusing fractionation and two-dimensional difference gel electrophoresis for low abundance serum proteins. Proteomics5(12), 3183–3192 (2005).
   PubMedGoogle Scholar
• Fountoulakis M, Langen H, Evers S, Gray C, Takacs B. Two-dimensional map of Haemophilus influenzae following protein enrichment by heparin chromatography. Electrophoresis18(7), 1193–1202 (1997).
   PubMedGoogle Scholar
• Fountoulakis M, Takacs MF, Takacs B. Enrichment of low-copy-number gene products by hydrophobic interaction chromatography. J. Chromatogr. A833(2), 157–168 (1999).
   PubMed Web of Science ®Google Scholar
• Washburn MP, Wolters D, Yates JR III. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat. Biotechnol.19(3), 242–247 (2001).
   PubMed Web of Science ®Google Scholar
• He P, He HZ, Dai J et al. The human plasma proteome: analysis of Chinese serum using shotgun strategy. Proteomics5(13), 3442–3453 (2005).
   PubMedGoogle Scholar
• Fernie AR, Geigenberger P, Stitt M. Flux an important, but neglected, component of functional genomics. Curr. Opin. Plant Biol.8(2), 174–182 (2005).
   PubMed Web of Science ®Google Scholar
• Krueger KE, Srivastava S. Posttranslational protein modifications: current implications for cancer detection, prevention, and therapeutics. Mol. Cell. Proteomics5(10), 1799–1810 (2006).
   PubMed Web of Science ®Google Scholar
• Kui Wong N, Easton RL, Panico M et al. Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125. J. Biol. Chem.278(31), 28619–28634 (2003).
   PubMed Web of Science ®Google Scholar
• Lloyd KO, Yin BW, Kudryashov V. Isolation and characterization of ovarian cancer antigen CA 125 using a new monoclonal antibody (VK-8): identification as a mucin-type molecule. Int. J. Cancer71(5), 842–850 (1997).
   PubMed Web of Science ®Google Scholar
• Hassan R, Remaley AT, Sampson ML et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin. Cancer Res.12(2), 447–453 (2006).
   PubMed Web of Science ®Google Scholar
• Hellstrom I, Raycraft J, Kanan S et al. Mesothelin variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol. Biomarkers Prev.15(5), 1014–1020 (2006).
   PubMed Web of Science ®Google Scholar
• Scholler N, Fu N, Yang Y et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc. Natl Acad. Sci. USA96(20), 11531–11536 (1999).
   PubMed Web of Science ®Google Scholar
• Onda M, Nagata S, Ho M et al. Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma. Clin. Cancer Res.12(14 Pt 1), 4225–4231 (2006).
   PubMed Web of Science ®Google Scholar
• Drapkin R, von Horsten HH, Lin Y et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res.65(6), 2162–2169 (2005).
   PubMed Web of Science ®Google Scholar
• Kingsmore SF. Multiplexed protein measurement: technologies and applications of protein and antibody arrays. Nat. Rev. Drug Discov.5(4), 310–320 (2006).
   PubMed Web of Science ®Google Scholar
• Lokshin AE, Winans M, Landsittel D et al. Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. Gynecol. Oncol.102(2), 244–251 (2006).
   PubMed Web of Science ®Google Scholar
• Hogdall EV, Hogdall CK, Blaakaer J et al. P53 autoantibodies in sera from Danish ovarian cancer patients and their correlation with clinical data and prognosis. APMIS110(7–8), 545–553 (2002).
   PubMed Web of Science ®Google Scholar
• Yousef GM, Polymeris ME, Yacoub GM et al. Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res.63(9), 2223–2227 (2003).
   PubMed Web of Science ®Google Scholar
• Anderson L, Seilhamer J. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis18(3–4), 533–537 (1997).
   PubMed Web of Science ®Google Scholar
• Sanchez-Carbayo M. Antibody arrays: technical considerations and clinical applications in cancer. Clin. Chem.52(9), 1651–1659 (2006).
   PubMed Web of Science ®Google Scholar
• Wang X, Yu J, Sreekumar A et al. Autoantibody signatures in prostate cancer. N. Engl. J. Med.353(12), 1224–1235 (2005).
   PubMed Web of Science ®Google Scholar
• Chatterjee M, Mohapatra S, Ionan A et al. Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res.66(2), 1181–1190 (2006).
   PubMed Web of Science ®Google Scholar
• Hood L, Heath JR, Phelps ME, Lin B. Systems biology and new technologies enable predictive and preventative medicine. Science306(5696), 640–643 (2004).
   PubMed Web of Science ®Google Scholar
• Hanash S. Integrated global profiling of cancer. Nat. Rev. Cancer4(8), 638–644 (2004).
   PubMed Web of Science ®Google Scholar
• Lu KH, Patterson AP, Wang L et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin. Cancer Res.10(10), 3291–3300 (2004).
   PubMed Web of Science ®Google Scholar
• Bast RC Jr, Urban N, Shridhar V et al. Early detection of ovarian cancer: promise and reality. Cancer Treat Res.107, 61–97 (2002).
   PubMedGoogle Scholar